Paper39765338
Efficacy of Combined Therapy With Silodosin and Solifenacin in Females With Overactive Bladder.
Jeon BJ and 5 others. Int Neurourol J, 2024. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Efficacy of Combined Therapy With Silodosin and Solifenacin in Females With Overactive Bladder. Papers, record 39765338. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39765338
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Efficacy of Combined Therapy With Silodosin and Solifenacin in Females With Overactive Bladder.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT07822113 | A Multicenter Randomized Cross-Over Study Evaluating the Efficacy and Safety of Silodosin in Adult Women With Voiding Dysfunction | Background |
Source ClinicalTrials.gov
References18
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 6823355 | Voiding difficulties in the female: prevalence, clinical and urodynamic review. | Obstet Gynecol | 1983 | https://conductscience.org/library/papers/6823355 | PubMed |
| 2 | 26663648 | A 12-Week, Open Label, Multi-Center Study to Evaluate the Clinical Efficacy and Safety of Silodosin on Voiding Dysfunction in Patients with Neurogenic Bladder. | Low Urin Tract Symptoms | 2015 | https://conductscience.org/library/papers/26663648 | PubMed |
| 3 | 28072862 | Efficacy and Safety of Initial Combination Treatment of an Alpha Blocker with an Anticholinergic Medication in Benign Prostatic Hyperplasia Patients with Lower Urinary Tract Symptoms: Updated Meta-Analysis. | PLoS One | 2017 | https://conductscience.org/library/papers/28072862 | PubMed |
| 4 | 19693954 | Urodynamic effects of silodosin, a new alpha 1A-adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia. | Neurourol Urodyn | 2010 | https://conductscience.org/library/papers/19693954 | PubMed |
| 5 | 34721668 | Effect of the symptom-based alpha-blocker treatment on lower urinary tract symptoms in women: systematic review and meta-analysis. | Ther Adv Urol | 2021 | https://conductscience.org/library/papers/34721668 | PubMed |
| 6 | 22983886 | Tamsulosin for voiding dysfunction in women. | Int Urol Nephrol | 2012 | https://conductscience.org/library/papers/22983886 | PubMed |
| 7 | 29609420 | Efficacy of an Alpha-Blocker for the Treatment of Nonneurogenic Voiding Dysfunction in Women: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Trial. | Int Neurourol J | 2018 | https://conductscience.org/library/papers/29609420 | PubMed |
| 8 | 19941278 | An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. | Neurourol Urodyn | 2010 | https://conductscience.org/library/papers/19941278 | PubMed |
| 9 | 21617983 | Efficacy and safety of combined therapy with tamsulosin and tolterodine in female patients with a maximal flow rate less than 12 ml/s. | Int Urogynecol J | 2011 | https://conductscience.org/library/papers/21617983 | PubMed |
| 10 | 39140022 | Therapeutic effectiveness and adverse drug reactions of mirabegron versus solifenacin in the treatment of overactive bladder syndrome. | Perspect Clin Res | 2024 | https://conductscience.org/library/papers/39140022 | PubMed |
| 11 | 24361007 | Antimuscarinics and α-blockers or α-blockers monotherapy on lower urinary tract symptoms--a meta-analysis. | Urology | 2014 | https://conductscience.org/library/papers/24361007 | PubMed |
| 12 | 28954464 | Meta-Analysis of the Efficacy and Safety of Mirabegron Add-On Therapy to Solifenacin for Overactive Bladder. | Int Neurourol J | 2017 | https://conductscience.org/library/papers/28954464 | PubMed |
| 13 | 31327266 | Alpha-Blocker Use and the Risk of Hypotension and Hypotension-Related Clinical Events in Women of Advanced Age. | Hypertension | 2019 | https://conductscience.org/library/papers/31327266 | PubMed |
| 14 | 21788967 | Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. | Prostate Cancer Prostatic Dis | 2011 | https://conductscience.org/library/papers/21788967 | PubMed |
| 15 | 16893438 | Solifenacin significantly improves all symptoms of overactive bladder syndrome. | Int J Clin Pract | 2006 | https://conductscience.org/library/papers/16893438 | PubMed |
| 16 | 24615630 | α-adrenergic blockers for the treatment of lower-urinary-tract symptoms and dysfunction in women. | Ann Pharmacother | 2014 | https://conductscience.org/library/papers/24615630 | PubMed |
| 17 | 19898824 | Prevalence of overactive bladder, urinary incontinence, and lower urinary tract symptoms: results of Korean EPIC study. | World J Urol | 2011 | https://conductscience.org/library/papers/19898824 | PubMed |
| 18 | 33567116 | Anticholinergics combined with alpha-blockers for treating lower urinary tract symptoms related to benign prostatic obstruction. | Cochrane Database Syst Rev | 2021 | https://conductscience.org/library/papers/33567116 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40903563 | Novel spectrophotometric approaches for analysis of solifenacin and silodosin in pharmaceutical preparations, human plasma, and environmental water samples: assessment of the methods' greenness and practicality. | Anal Bioanal Chem | 2025 | https://conductscience.org/library/papers/40903563 | PubMed |
| 39765336 | Innovation and the Importance of Patient-Centered Treatment. | Int Neurourol J | 2024 | https://conductscience.org/library/papers/39765336 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39765338
GET https://conductscience.org/api/papers/v1/39765338/authors